SAN DIEGO, Oct. 31, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral artery disease, said today that revenues for the third quarter of 2011 increased 18 percent versus the third quarter of 2010.
For the quarter ended September 30, 2011, Volcano reported revenues of $85.8 million versus revenues of $72.9 million in the third quarter a year ago. Year-over-year medical segment revenues increased 24 percent in the third quarter of 2011. Industrial segment revenues in the third quarter declined 54 percent versus a year ago, due to reduced spending in the telecommunications sector.
The company reported net income on a GAAP basis of $2.6 million, or $0.05 per diluted share, in the third quarter of 2011, versus net income of $5.6 million, or $0.10 per diluted share, in the third quarter of 2010.
For the first nine months of 2011, Volcano reported revenues of $250.8 million, an 18 percent increase over revenues of $212.9 million in the same period a year ago. The company reported GAAP net income of $8.7 million, or $0.16 per diluted share, in the first nine months of 2011. This compares with GAAP net income of $7.0 million, or $0.13 per diluted share, in the same period in 2010.
"Volcano's medical segment business experienced solid growth in the third quarter, driven by a 48 percent increase in FFR (Fractional Flow Reserve) disposable revenues, as FFR continued its higher market penetration and we continued to gain market share for both our FFR and IVUS (Intravascular Ultrasound) businesses in key geographies. These gains occurred despite a challenging macro-economic environment that is impacting procedure activity, particularly for our IVUS business," said Scott Huennekens, president and chief executive officer.
"Given the increased focus on comparative effectiveness, we continue to be optimistic about the long-term prospects for our current and future offerings—particularly IVUS—as recent data from the Matrix study reinforces positive outcomes with respect to reduction in deaths and adverse events when using IVUS versus the use of angiography alone," he added.
Huennekens said the company continues to advance its long-term growth strategy. "We are making investments in product development and clinical programs to further our vision as the leading therapy guidance company with a platform that delivers precision guided therapy and diagnosis utilizing intravascular imaging, physiology and future technologies. Over the next year, we will be introducing enhancements to our current offerings, as well as new products that will enable us to address new markets," he noted.
Guidance for 2011
The company said that given current expectations for healthcare procedure activity and telecom business sales, it is narrowing the top range of its revenue guidance for fiscal 2011 from $342-$347 million to $342-$345 million. It continues to expect that gross margin will be 65-66 percent and that operating expenses will be 58-60 percent of revenues. The company expects earnings per diluted share for fiscal 2011 will be $0.19-$0.21. The company said that as a result of its projected ongoing GAAP profitability, it is assessing its ability to release a portion of its deferred tax valuation allowance, which may result in additional estimated net income of approximately $25.0 million, or $0.45 per diluted share, in the fourth quarter of 2011.
Conference Call Information
The company will hold a conference call at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time), today. The teleconference can be accessed by calling (631) 291-4555, passcode 14128534, or via the company's website at http://www.volcanocorp.com. Please dial in or access the webcast 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available through November 7, at (404) 537-3406 passcode 14128534, and via the company's website at http://www.volcanocorp.com.
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information—using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at www.volcanocorp.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the risk that Volcano's revenue, expense or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts and the risk of further adjustment, or unanticipated difficulty in achieving those projections, the effect of competitive and economic factors, and the company's reaction to those factors, on purchasing decisions with respect to the company's products, the pace and extent of market adoption of the company's products and technologies, the inherent uncertainty in the process of obtaining regulatory approval or clearance for Volcano's products or devices, the success of Volcano's growth strategies, risks associated with Volcano's international operations, the impact of the recent events in Japan, timing and achievement of product development milestones, outcome of ongoing litigation, the impact and benefits of market development, dependence upon third parties, product introductions, unexpected new data, safety and technical issues, market conditions and other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent annual report on Form 10-K for the year ended December 31, 2010, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.VOLCANO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (Unaudited) September 30, December 31,20112010 Assets Current assets: Cash and cash equivalents
43,429 Short-term available-for-sale investments
154,314175,283 Accounts receivable, net
46,46340,499 Prepaid expenses and other current assets
8,6736,643 Total current assets
325,954324,987 Long-term available-for-sale investments
33,92826,804 Property and equipment, net
73,41156,503 Intangible assets, net
2,4872,487 Other non-current assets
431,566 Liabilities and Stockholders' Equity Current liabilities: Accounts payable
3,895 Accrued compensation
15,68718,241 Accrued expenses and other current liabilities
14,10221,960 Deferred revenues
6,4235,898 Current maturities of long-term debt
7256 Total current liabilities
49,00060,050 Long-term debt
94,54391,236 Deferred revenues
3,2153,478 Total liabilities
149,636157,230 Stockholders' equity
431,566VOLCANO CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(Unaudited)Three Months Ended
September 30,Nine Months Ended
212,910Cost of revenues29,53825,95584,17579,686Gross profit56,22946,931166,623133,224Operating expenses:Selling, general and administrative36,03429,565106,98292,726Research and development13,92810,18540,33729,637Amortization of intangibles8606272,5721,821In-process research and development---65Total operating expenses50,82240,377149,891124,249Operating income5,4076,55416,7328,975Interest income226106701274Interest expense(1,834)(249)(5,895)(267)Exchange rate loss(502)(91)(1,181)(635)Other--(2)(19)Income before provision for income taxes3,2976,32010,3558,328Provision for income taxes6697351,6841,363Net income
6,965Net income per share:Basic
0.13Shares used in calculating net income per share:Basic52,51750,81052,18850,339Diluted54,94753,27854,60553,032VOLCANO CORPORATIONREVENUE SUMMARY(in millions)(unaudited)Three Months Ended
September 30,Percentage Change Nine Months Ended
September 30,Percentage Change 201120102010 to 2011201120102010 to 2011Medical segment:Consoles:United States
$ 6.0$ 5.74
%$ 17.6$ 17.32
1.51.3136.35.221Rest of world
$ 9.7$ 8.119$ 29.4$ 27.67IVUS single-procedure disposables:United States
%$ 56.2$ 51.010
6.24.82717.815.316Rest of world
1.61.2324.83.631Total IVUS single-procedure disposables
$49.8$42.617$147.4$122.121FM single-procedure disposables:United States
$ 9.3$ 6.346
%$ 26.1$ 17.648
5.73.75417.011.350Rest of world
0.30.5(30)1.51.315Total FM single-procedure disposables
$16.7$11.348$ 47.9$ 32.547Other
%Sub-total medical segment
|SOURCE Volcano Corporation|
Copyright©2010 PR Newswire.
All rights reserved